EP0871672A1 - Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine - Google Patents
Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaineInfo
- Publication number
- EP0871672A1 EP0871672A1 EP95927260A EP95927260A EP0871672A1 EP 0871672 A1 EP0871672 A1 EP 0871672A1 EP 95927260 A EP95927260 A EP 95927260A EP 95927260 A EP95927260 A EP 95927260A EP 0871672 A1 EP0871672 A1 EP 0871672A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- polypeptide
- polynucleotide
- dna
- cellε
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
Definitions
- chemokines have been implicated in a number of physiological and disease condition ⁇ , including lymphocyte trafficking, wound healing, hematopoietic regulation and immunological di ⁇ order ⁇ ⁇ uch a ⁇ allergy, asthma and arthritis.
- MIP-1 wa ⁇ originally identified a ⁇ an endotoxin- induced proinflammatory cytokine produced from macrophage ⁇ .
- Subsequent studie ⁇ have ⁇ hown that MIP-l i ⁇ composed of two different, but related, protein ⁇ MlP-l ⁇ and MIP-l/3.
- nucleic acid probes comprising nucleic acid molecules of sufficient length to specifically hybridize to the Ck/3-8, Ck3-1 and MIP-4 nucleic acid sequence ⁇ .
- a proce ⁇ for utilizing such polypeptides, or polynucleotide ⁇ encoding such polypeptides, as research reagents for in vitro purpose ⁇ related to ⁇ cientific research, synthesi ⁇ of DNA and manufacture of DNA vector ⁇ , for the purpo ⁇ e of developing therapeutics and diagnostics for the treatment of human disease.
- FIG. 4 illustrate ⁇ the amino acid homology between Ck/3-8 (top) and human MlP-l ⁇ (bottom) .
- the four cy ⁇ teine ⁇ characteri ⁇ tic of all chemokine ⁇ are ⁇ hown.
- FIG. 12 The monocyte cell line THP-l wa ⁇ treated for 16 hour ⁇ with LPS (0.1-10 ng/ml) or Ck / 3-8 (to 50 ng/ml). Tissue culture supernatants were subjected to ELISA analysis to quantify the secretion of TNF- ⁇ .
- FIG. 18 Effect of Ck/3-8 and Ck/3-1 on the generation of GR-l and Mac-1 ( ⁇ urface marker ⁇ ) po ⁇ itive population of cells from lin" population of bone marrow cells.
- lin " cells were incubated in growth medium supplemented with IL-3 (5 ng/ml) and SCF (100 ng/ml) alone (a) and Ck/3-8 (50 ng/ml) (b) or Ck/3-l (50 ng/ml) .
- Cells were then stained with Monoclonal antibodies against myeloid differentiation GR.l, Mac-1, Sca- 1, and CD45R surface antigens and analyzed by FACScan. Data is presented as percentage of positive cell ⁇ in both large (A) and ⁇ mall (B) cell population ⁇ .
- FIG. 19 illustrates that the presence of Ck/3-8 (+) inhibits bone marrow cell colony formation in respon ⁇ e to IL- 3, M-CSF and GM-CSF.
- nucleic acid ⁇ (polvnucleotide ⁇ ) which encode for the mature polypeptide ⁇ having the deduced amino acid sequence of Figures l, 2 and 3 (SEQ ID No. 2, 4 and 6, respectively) or for the mature Ck/3-8 polypeptide encoded by the cDNA of the clone(s) depo ⁇ ited a ⁇ ATCC Depo ⁇ it No. 75676 on February 9, 1994, and for the mature MIP-4 polypeptide encoded by the cDNA of the clone depo ⁇ ited a ⁇ ATCC Depo ⁇ it No. 75675 on February 9, 1994 and for the mature Ck/3-1 polypeptide encoded by the cDNA of the clone depo ⁇ ited a ⁇ ATCC Depo ⁇ it No. 75572, depo ⁇ ited on October 13, 1993.
- the polynucleotides of the present invention may also have the coding sequence fused in frame to a marker sequence which allows for purification of the polypeptides of the present invention.
- the marker sequence may be a hexa- hi ⁇ tidine tag supplied by a pQE-9 vector to provide for purification of the mature polypeptides fused to the marker in the case of a bacterial host, or, for example, the marker sequence may be a hemagglutinin (HA) tag when a mammalian host, e.g. COS-7 cells, is used.
- the HA tag correspond ⁇ to an epitope derived from the influenza hemagglutinin protein (Wilson, I., et al., Cell, 37:767 (1984)).
- the fragment, derivative or analog of the polypeptides of Figures 1, 2 and 3 (SEQ ID No. 2, 4 and 6) or that encoded by the deposited cDNA may be (i) one in which one or more of the amino acid residues are sub ⁇ tituted with a conserved or non-conserved amino acid residue (preferably a conserved amino acid residue) and such sub ⁇ tituted amino acid re ⁇ idue may or may not be one encoded by the genetic code, or (ii) one in which one or more of the amino acid re ⁇ idue ⁇ include ⁇ a substituent group, or (iii) one in which the mature polypeptide ⁇ are fu ⁇ ed with another compound, ⁇ uch a ⁇ a compound to increa ⁇ e the half-life of the polypeptide (for example, polyethylene glycol) , or (iv) one in which the additional amino acid ⁇ are fu ⁇ ed to the mature polypeptide ⁇ , such as a leader or secretory sequence or a sequence which is employed for purification
- the pre ⁇ ent invention al ⁇ o include ⁇ recombinant con ⁇ truct ⁇ compri ⁇ ing one or more of the ⁇ equence ⁇ a ⁇ broadly de ⁇ cribed above.
- the con ⁇ truct ⁇ compri ⁇ e a vector, ⁇ uch a ⁇ a pla ⁇ mid or viral vector, into which a ⁇ equence of the invention ha ⁇ been inserted, in a forward or reverse orientation.
- the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence. Large numbers of suitable vector ⁇ and promoters are known to those of skill in the art, and are commercially available.
- the following vector ⁇ are provided by way of example.
- mutation ⁇ can al ⁇ o be detected by in situ analy ⁇ i ⁇ .
- a detectable reagent such as a ⁇ radioactivity, fluore ⁇ cence or, in thi ⁇ example, a hor ⁇ eradi ⁇ h peroxida ⁇ e enzyme.
- a ⁇ araple i ⁇ removed from a ho ⁇ t and incubated on a ⁇ olid ⁇ upport, e.g. a_ poly ⁇ tyrene di ⁇ h, that bind ⁇ the protein ⁇ in the ⁇ ample. Any free protein binding ⁇ ite ⁇ on the di ⁇ h are then covered by incubating with a non-specific protein like BSA.
- the vector ⁇ include one or more ⁇ uitable promoter ⁇ which include, but are not limited to, the retroviral LTR; the SV40 promoter; and the human cytomegaloviru ⁇ (CMV) promoter de ⁇ cribed in Miller, et al., Biotechni ⁇ ue ⁇ , Vol. 7, No. 9, 980-990 (1989) , or any other promoter (e.g., cellular promoter ⁇ ⁇ uch a ⁇ eukaryotic cellular promoters including, but not limited to, the hi ⁇ tone, pol III, and /3-actin promoters) .
- a suitable promoter will be apparent to those skilled in the art from the teachings contained herein.
- the polypeptide ⁇ , their fragment ⁇ or other derivatives, or analogs thereof, or cells expres ⁇ ing them can be u ⁇ ed a ⁇ an immunogen to produce antibodies thereto.
- These antibodies can be, for example, polyclonal or monoclonal antibodie ⁇ .
- the pre ⁇ ent invention al ⁇ o include ⁇ chimeric, single chain and humanized antibodies, as well as Fab fragments, or the product of an Fab expre ⁇ ion library. Variou ⁇ procedure ⁇ known in the art may be u ⁇ ed for the production of ⁇ uch antibodie ⁇ and fragment ⁇ .
- the DNA ⁇ equence encoding Ck/3-8, ATCC # 75676, wa ⁇ initially amplified u ⁇ ing PCR oligonucleotide primer ⁇ corre ⁇ ponding to the 5' and 3' end ⁇ equences of the processed Ck/3-8 protein (minus the ⁇ ignal peptide sequence) and the vector sequence ⁇ 3' to the Ck/3-8 gene. Additional nucleotide ⁇ corre ⁇ ponding to Bam HI and Xbal were added to the 5' and 3' ⁇ equence ⁇ re ⁇ pectively.
- the 5' oligonucleotide primer ha ⁇ the sequence 5' TCAGGATCCGTCACAAAAGATGCAGA 3' (SEQ ID No.
- PQE-9 encode ⁇ antibiotic resistance (Amp r ) , a bacterial origin of replication (ori) , an IPTG-regulatable promoter operator (P/0) , a ribosome binding ⁇ ite (RBS) , a 6-Hi ⁇ tag and restriction enzyme ⁇ ite ⁇ .
- pQE-9 was then digested with BamHI and Xbal and the amplified sequence ⁇ were ligated into PQE-9 and were in ⁇ erted in frame with the ⁇ equence encoding for the histidine tag and the RBS.
- the ligation mixture wa ⁇ then used to transform E. coli strain available from Qiagen under the trademark M15/rep 4.
- CMV-MIP-4 HA i ⁇ derived from a vector pcDNAI/Amp (Invitrogen) containing: 1) SV40 origin of replication, 2) ampicillin re ⁇ i ⁇ tance gene, 3) E.coli replication origin, 4) CMV promoter followed by a polylinker region, a SV40 intron and polyadenylation ⁇ ite.
- a DNA fragment encoding the entire MIP-4 precur ⁇ or and a HA tag fu ⁇ ed in frame to its 3' end is cloned into the polylinker region of the vector, therefore, the recombinant protein expression is directed under the CMV promoter.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US44688195A | 1995-05-05 | 1995-05-05 | |
US446881 | 1995-05-05 | ||
PCT/US1995/009058 WO1996034891A1 (fr) | 1995-05-05 | 1995-06-23 | Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0871672A1 true EP0871672A1 (fr) | 1998-10-21 |
EP0871672A4 EP0871672A4 (fr) | 1999-05-12 |
Family
ID=23774170
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95927260A Withdrawn EP0871672A4 (fr) | 1995-05-05 | 1995-06-23 | Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0871672A4 (fr) |
JP (2) | JPH11505417A (fr) |
KR (1) | KR19990008335A (fr) |
CN (2) | CN1125082C (fr) |
AU (1) | AU3134695A (fr) |
CA (1) | CA2220123A1 (fr) |
MX (1) | MX9708537A (fr) |
WO (1) | WO1996034891A1 (fr) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6488925B2 (en) | 1993-12-22 | 2002-12-03 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-4 (MIP-4) polypeptides |
US6811773B1 (en) | 1993-12-22 | 2004-11-02 | Human Genome Sciences, Inc. | Human monocyte colony inhibitory factor (M-CIF) polypeptides |
US6001606A (en) * | 1994-03-08 | 1999-12-14 | Human Genome Sciences, Inc. | Polynucleotides encoding myeloid progenitor inhibitory factor-1 (MPIF-1) and polypeptides encoded thereby |
US6495129B1 (en) | 1994-03-08 | 2002-12-17 | Human Genome Sciences, Inc. | Methods of inhibiting hematopoietic stem cells using human myeloid progenitor inhibitory factor-1 (MPIF-1) (Ckbeta-8/MIP-3) |
US6623942B2 (en) | 1994-03-08 | 2003-09-23 | Human Genome Sciences, Inc. | Macrophage inflammatory protein-4 (MIP-4) polynucleotides |
EA199800352A1 (ru) * | 1995-09-29 | 1998-12-24 | Смитклайн Бичам Корпорейшн | ПОЛИПЕПТИД ХЕМОКИНА β-8 (ВАРИАНТЫ) И СПОСОБ ЕГО ПОЛУЧЕНИЯ, КОМПОЗИЦИИ ПОЛИПЕПТИДОВ, ВЕКТОР, КЛЕТКА-ХОЗЯИН, АГОНИСТ И АНТАГОНИСТ, ВСЕ - УПОМЯНУТОГО ПОЛИПЕПТИДА, И СПОСОБ ИДЕНТИФИКАЦИИ ПОСЛЕДНЕГО, СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В Хк-β-8 (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ БОЛЬНОГО, ИСПЫТЫВАЮЩЕГО ПОТРЕБНОСТЬ В ПОДАВЛЕНИИ Хк-β-8, СПОСОБ ДИАГНОСТИКИ ЗАБОЛЕВАНИЯ ИЛИ ПРЕДРАСПОЛОЖЕННОСТИ К ЗАБОЛЕВАНИЮ, ОБУСЛОВЛЕННОМУ НЕДОСТАТОЧНОЙ ЭКСПРЕССИЕЙ ПОЛИПЕПТИДА |
US6512103B1 (en) | 1995-12-08 | 2003-01-28 | Schering Corporation | Mammalian chemokine reagents |
US7888466B2 (en) | 1996-01-11 | 2011-02-15 | Human Genome Sciences, Inc. | Human G-protein chemokine receptor HSATU68 |
ATE317012T1 (de) * | 1996-04-30 | 2006-02-15 | Pharis Biotec Gmbh | Chemokine vom cc-typ |
NZ506135A (en) * | 1996-09-30 | 2002-11-26 | Human Genome Sciences Inc | Monocyte colony inhibitory factor (M-CIF) derivatives and their use in treating sepsis |
US5912327A (en) * | 1996-09-30 | 1999-06-15 | Human Genome Sciences, Inc. | Method of purifying chemokines from inclusion bodies |
US6632425B1 (en) | 1997-03-20 | 2003-10-14 | Human Genome Sciences, Inc. | Chemokine compositions |
DK1015477T3 (da) | 1997-05-30 | 2011-02-07 | Human Genome Sciences Inc | 32 humane sekreterede proteiner |
WO1999023105A1 (fr) | 1997-11-03 | 1999-05-14 | Human Genome Sciences, Inc. | Vegi, un inhibiteur de l'angiogenese et de la croissance tumorale |
KR19990042713A (ko) * | 1997-11-27 | 1999-06-15 | 허일섭 | 사람에서 분리한 c 6 베타-케모카인 lkn-1의 cdna 및 재조합 lkn-1의 제조방법 |
CA2323776C (fr) | 1998-03-19 | 2010-04-27 | Human Genome Sciences, Inc. | Analogue de chaine gamma commune de recepteur de cytokine |
AU4818599A (en) * | 1998-07-06 | 2000-01-24 | Schering Corporation | Mammalian genes; dendritic cell prostaglandin-like transponder (dc-pgt), hdtea84, hsljd37r and rankl, hcc5 chemokine, deubiquitinating 11 and 12 (dub11, dub12),md-1, md2 and cyclin e2, related reagents and methods |
EP0974357A1 (fr) | 1998-07-16 | 2000-01-26 | Schering-Plough | Chemokines comme adjuvants de la réponse immunitaire |
US6495128B1 (en) | 1998-11-10 | 2002-12-17 | Human Genome Sciences, Inc. | Human chemokine β-7 deletion and substitution proteins |
JP2003516934A (ja) * | 1999-10-14 | 2003-05-20 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | ヒト骨髄前駆細胞阻害性因子−1(mpif−1)を用いる、細胞、組織および器官の損傷を処置または予防する方法 |
WO2001031016A2 (fr) * | 1999-10-25 | 2001-05-03 | Euroscreen S.A. | Chimiokines humaines phc-1 et phc-2 traitees |
EP1167527A1 (fr) * | 2000-06-22 | 2002-01-02 | Euroscreen S.A. | Chemokines humaines tronquées: PHC-1 et PHC-2 |
CA2405709A1 (fr) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Proteines fusionnees a l'albumine |
AU2001282856A1 (en) | 2000-06-15 | 2001-12-24 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta and epsilon |
EP1176200A3 (fr) | 2000-06-20 | 2005-01-12 | Switch Biotech Aktiengesellschaft | Utilisation des polypeptides ou leurs acides nucléiques pour le diagnose ou traitement des maladies de la peau ou de la cicatrisation de blessures et leurs utilisations pour l'identification des substances pharmacologiquement actives |
AU2001271621A1 (en) | 2000-06-28 | 2002-01-08 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
AU8847801A (en) | 2000-08-25 | 2002-03-04 | Basf Plant Science Gmbh | Plant polynucleotides encoding novel prenyl proteases |
US6989247B2 (en) | 2000-11-28 | 2006-01-24 | Celltech R & D, Inc. | Compositions and methods for diagnosing or treating psoriasis |
EP1692171B1 (fr) | 2003-12-05 | 2009-06-03 | Oxagen Limited | Agents modulateurs de l'activite de ccrl2 et methodes les utilisant |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
EP2054437A2 (fr) | 2006-08-07 | 2009-05-06 | Teva Biopharmaceuticals USA, Inc. | Protéines de fusion d'albumine et d'insuline |
WO2012116453A1 (fr) | 2011-03-03 | 2012-09-07 | Zymeworks Inc. | Conception et constructions d'échafaudage hétéromultimère multivalent |
AU2013289881B2 (en) | 2012-07-13 | 2018-01-18 | Zymeworks Bc Inc. | Multivalent heteromultimer scaffold design and constructs |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005198A1 (fr) * | 1990-09-14 | 1992-04-02 | Chiron Corporation | Expression de proteines inductibles par macrophages (mip) dans des cellules de levure |
WO1995017092A1 (fr) * | 1993-12-22 | 1995-06-29 | Human Genome Sciences, Inc. | PROTEINES-3, -4 ET 1η INFLAMMATOIRES MACROPHAGES |
WO1995018228A1 (fr) * | 1993-12-24 | 1995-07-06 | Forssmann Wolf Georg | Cytokine humaine circulante cc-1 |
WO1996016979A1 (fr) * | 1994-11-29 | 1996-06-06 | Incyte Pharmaceuticals, Inc. | Production et utilisation des chimiokines exprimees |
WO1996032481A1 (fr) * | 1995-04-13 | 1996-10-17 | Incyte Pharmaceuticals, Inc. | Nouvelle chimioquine exprimee dans des eosinophiles |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR950008571B1 (ko) * | 1986-01-08 | 1995-08-03 | 롱쁠랑 아그로시미 | 할로아릴니트릴 분해 유전자, 그의 용도 및 이를 함유한 세포 |
-
1995
- 1995-06-23 KR KR1019970707861A patent/KR19990008335A/ko not_active Application Discontinuation
- 1995-06-23 EP EP95927260A patent/EP0871672A4/fr not_active Withdrawn
- 1995-06-23 CN CN95197892A patent/CN1125082C/zh not_active Expired - Fee Related
- 1995-06-23 AU AU31346/95A patent/AU3134695A/en not_active Abandoned
- 1995-06-23 CN CNA021471495A patent/CN1515672A/zh active Pending
- 1995-06-23 WO PCT/US1995/009058 patent/WO1996034891A1/fr not_active Application Discontinuation
- 1995-06-23 JP JP8533269A patent/JPH11505417A/ja not_active Ceased
- 1995-06-23 CA CA002220123A patent/CA2220123A1/fr not_active Abandoned
- 1995-06-23 MX MX9708537A patent/MX9708537A/es unknown
-
2002
- 2002-06-21 JP JP2002181851A patent/JP2003102486A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005198A1 (fr) * | 1990-09-14 | 1992-04-02 | Chiron Corporation | Expression de proteines inductibles par macrophages (mip) dans des cellules de levure |
WO1995017092A1 (fr) * | 1993-12-22 | 1995-06-29 | Human Genome Sciences, Inc. | PROTEINES-3, -4 ET 1η INFLAMMATOIRES MACROPHAGES |
WO1995018228A1 (fr) * | 1993-12-24 | 1995-07-06 | Forssmann Wolf Georg | Cytokine humaine circulante cc-1 |
WO1996016979A1 (fr) * | 1994-11-29 | 1996-06-06 | Incyte Pharmaceuticals, Inc. | Production et utilisation des chimiokines exprimees |
WO1996032481A1 (fr) * | 1995-04-13 | 1996-10-17 | Incyte Pharmaceuticals, Inc. | Nouvelle chimioquine exprimee dans des eosinophiles |
Non-Patent Citations (1)
Title |
---|
See also references of WO9634891A1 * |
Also Published As
Publication number | Publication date |
---|---|
CN1515672A (zh) | 2004-07-28 |
WO1996034891A1 (fr) | 1996-11-07 |
CN1186501A (zh) | 1998-07-01 |
EP0871672A4 (fr) | 1999-05-12 |
JPH11505417A (ja) | 1999-05-21 |
KR19990008335A (ko) | 1999-01-25 |
AU3134695A (en) | 1996-11-21 |
CA2220123A1 (fr) | 1996-11-07 |
CN1125082C (zh) | 2003-10-22 |
JP2003102486A (ja) | 2003-04-08 |
MX9708537A (es) | 1998-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996034891A1 (fr) | Chimiokine beta-8, chimiokine beta-1 et proteine 4 inflammatoire des macrophages d'origine humaine | |
WO1995017092A1 (fr) | PROTEINES-3, -4 ET 1η INFLAMMATOIRES MACROPHAGES | |
AU696764C (en) | Vascular endothelial growth factor 2 | |
WO1996039515A9 (fr) | Facteur de croissance endotheliale vasculaire 2 humain | |
EP0837934A1 (fr) | Facteur de croissance endotheliale vasculaire 2 humain | |
AU7672394A (en) | Human chemokine polypeptides | |
WO1996034095A1 (fr) | Recepteurs du facteur de necrose tumorale chez l'homme | |
US6867006B2 (en) | Antibodies to human chemotactic protein | |
WO1995024414A1 (fr) | Facteur-10 de croissance du fibroblaste | |
EP0799311A1 (fr) | Chemokine beta 9 humaine | |
EP0815137A1 (fr) | Chemokine recepteur hdgnr10 aux proteines g humaines | |
WO1996028546A1 (fr) | Recepteur humain du facteur de necrose tumorale | |
EP0832233A1 (fr) | Chemokine beta-13 humaine | |
EP0811059A1 (fr) | Chemokine humaine beta-11 et chemokine humaine alpha-1 | |
WO1995031468A1 (fr) | Facteur-3 inhibiteur de la migration des macrophages | |
WO1997002280A1 (fr) | Genes et proteines specifiques au sein | |
WO1995032282A1 (fr) | Variant d'epissure d'interleukine-6 | |
WO1996039507A1 (fr) | Facteur 11 de croissance des fibroblastes | |
US5880263A (en) | Human chemotactic protein | |
WO1997034013A1 (fr) | Cytokine ii chimiotactique | |
WO1996039497A1 (fr) | Facteur de croissance transformant alpha hi | |
AU684539C (en) | Macrophage inflammatory proteins-3, -4 and -1 Gamma | |
EP0777494A1 (fr) | Polypeptides de type chemokine humaine | |
WO1997032993A1 (fr) | Cytokine iii chimiotactique | |
EP0819168A1 (fr) | Recepteur humain du facteur de necrose tumorale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19971205 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19990329 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
17Q | First examination report despatched |
Effective date: 20030630 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20050903 |